volasertib + idarubicin + cytarabine

This combination regimen consists of volasertib, idarubicin, and cytarabine, investigated for the treatment of previously untreated acute myeloid leukemia (AML). Volasertib (BI 6727) is a potent, ATP-competitive small molecule inhibitor of polo-like kinases, primarily targeting PLK1, which is a critical regulator of the cell cycle. By inhibiting PLK1, volasertib induces G2-M phase arrest and apoptosis in malignant cells. In this specific regimen, volasertib is added to standard intensive induction chemotherapy, which includes idarubicin (an anthracycline that intercalates DNA and inhibits topoisomerase II) and cytarabine (a pyrimidine analog that inhibits DNA synthesis). The University of Alberta sponsored the Phase I VIAC trial to determine the safety and maximum tolerated dose of this triplet combination in AML patients.

Other names

VIAC regimenVolasertib combined with standard induction chemotherapyVolasertib + Idarubicin + Cytarabine